Reviews/Dry Eye Disease Treatment/Cyclosporine reduces corneal staining
Cyclosporine · DED-CYC-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Dry eye disease damages the surface of the cornea, and clinicians measure that damage by applying a dye and counting the stained spots. Across several large, well-designed trials that compared cyclosporine eye drops against an identical dummy drop, people using cyclosporine ended up with fewer stained spots on the cornea [2], [6], [7], [8], [10]. The improvement was usually small, and the dummy drops also helped a lot, so the gap between the two was modest [6], [4]. One smaller trial found no meaningful difference in staining by week 12 [14]. Because these trials measured corneal staining directly rather than inferring it from something else, and because the same direction appeared across different formulations and manufacturers, the panel concluded the reduction is real even though it is not large.
Multiple large double-masked vehicle-controlled phase 3 trials report that cyclosporine reduces total corneal fluorescein staining versus vehicle, several as a pre-specified primary endpoint [2], [6], [7], [10], and OTX-101 showed significant corneal staining improvement at days 28, 56 and 84 [8]. The direction is consistent across formulations, sponsors and countries [1], [3], [10]. Effect sizes are modest: ESSENCE-2 reported a between-group difference of Δ = -0.4 on a 0-15 scale (P = .03) [6], while the water-free solution reached a tCFS difference of Δ = -1.8 (P < .001) at day 29 [2]. Active-comparator and retrospective studies also show lower staining with cyclosporine but lack a placebo arm [9], [12], [13]. The contested point: The division is over magnitude and robustness, not direction. Vehicle arms improve substantially, narrowing the separation [4], [6]; SANSIKA missed its composite primary endpoint (28.6% vs 23.1%, p = 0.326), with the staining benefit surviving only as a continuous secondary reading (p = 0.037) [3]; and one trial found the fluorescein staining change not significant at week 12 (P = 0.706) [14].
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Effect sizes are modest and vehicle arms improve substantially, narrowing separation; ESSENCE-2 [6] Δ=-0.4 on a 0-15 scale (P=.03) is statistically but marginally significant, and [4] notes the vehicle 'performed well, perhaps because of its long residence time on the ocular surface'.
SANSIKA [3] missed its composite primary endpoint (28.6% vs 23.1%, p=0.326); the corneal staining benefit survives only as a continuous secondary reading (p=0.037).
Where it remains uncertain. Effect sizes are small with strong vehicle responses [6], [4], SANSIKA missed its composite primary endpoint [3], and one trial found no significant staining change at week 12 [14].
Aleatory
The week-12 fluorescein staining change in the 80-eye trial was not significant (P=0.706), consistent with random variation at small sample size [14].
Epistemic
Vehicle arms improve substantially, and [4] notes the vehicle performed well perhaps because of its long residence time on the ocular surface, so the true drug-specific increment is uncertain [6], [4].
Inferential
Active-comparator and retrospective designs cannot separate cyclosporine's staining effect from background therapy or regression to the mean [9], [12], [13].
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Reduction vs both vehicle and active comparator
“CyclASol showed a consistent reduction in corneal and conjunctival staining compared with both vehicle and Restasis over the 16-week treatment period, with an early onset of effect (at day 14).”
Panel auditInternal validity: high · scope of inference: Moderate-to-severe DED adults treated twice daily for 16 weeks with a waterfree cyclosporine formulation.Key limitations: exploratory phase II · total corneal staining only borderline (P<0.1) · specific waterfree formulation
Phase 3 RCT, significant tCFS reduction vs vehicle
“At day 29, the cyclosporine group experienced improved tCFS compared with vehicle (change [Δ] = -1.8; 95% CI, -2.7 to -1.0; P < .001), with a tCFS score decrease from baseline of -4.8 in the cyclosporine group and -3.0 in the vehicle group.”
Panel auditInternal validity: high · scope of inference: Moderate-to-severe DED in Chinese adults, 29-day treatment.Key limitations: single-country population · short 29-day primary window · specific water-free formulation
Largest RCT (N=834); significant but small staining benefit
“Participants treated with cyclosporine solution had greater improvement in tCFS (-4.0 grades) than the vehicle group (-3.6 grades) at day 29 (change [∆] = -0.4; 95% CI, -0.8 to 0; P = .03).”
Panel auditInternal validity: high · scope of inference: Moderate-to-severe DED adults, 29-day treatment.Key limitations: small absolute effect (CI upper bound 0) · short 29-day window · specific water-free formulation
Significant continuous CFS benefit despite composite primary miss
“Assessment of corneal damage showed greater improvement with CsA CE over vehicle in mean adjusted CFS change from baseline to month 6 (-1.764 vs -1.418, p = 0.037).”
Panel auditInternal validity: high · scope of inference: Severe DED with baseline CFS grade 4, once-daily dosing over 6 months.Key limitations: corneal staining was secondary · composite primary endpoint not met · severe-only population
4 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Reproducible directional reduction on the exact outcome across multiple large RCTs supports an Established tier, held to the conservative end given modest effect sizes and one null.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Durable, clinically meaningful staining benefit. Effect sizes are small and one trial is null at week 12, so whether the reduction persists and matters clinically is unresolved [6], [14]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large vehicle-controlled RCT powered on a pre-specified corneal staining responder threshold with follow-up beyond 12 weeks.
Open question: Does the corneal staining reduction persist beyond 12 weeks of treatment? Why it is still open: The one trial reporting a week-12 staining outcome found it not significant (P=0.706) [14], while primary endpoints elsewhere were measured at days 29 to 84 [2], [6], [8].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19